PLENARY SPEAKER

Dr Justin Jang Hann Chu is currently the Assistant Dean for Academic Affairs and an Associate Professor in the Department of Microbiology and Immunology and Infectious Diseases Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore. He is holding a Joint Senior Principal Investigator position in the Institute of Molecular and Cell Biology (IMCB), A*STAR. Dr. Chu is also the Director of the largest research-based high containment Biosafety Level 3 Facility in Singapore, which is located in the Yong Loo Lin School of Medicine, NUS. Dr. Chu is actively engaged in the study of the molecular virology of positive-sense RNA viruses of medical importance, including SARS-CoV-2, human enteroviruses that cause HFMD, as well as mosquito-borne viruses including Dengue, Zika, West Nile and Chikungunya. The outcomes from these studies are helping to pave the roadmap towards the successful development of antiviral strategies, including vaccines and antiviral therapeutics. Fifteen patents and numerous scientific awards have been received from his current research.  Dr. Chu has published over 150 international peer-reviewed scientific publications, six book chapters and over 200 conference papers. A number of these scientific papers are published in top-notch journals, including Cell, Science, Nature Immunology, Science Translational Medicine, Nature Communications, PNAS, EBiomedicine, and PLoS Pathogens. Dr. Chu is among the World’s Top 2% Scientists ranking published by Stanford University based on single-year data on citations received during the calendar year 2021, 2022 and 2023. Dr. Chu is currently serving as the associate editor and reviewer for a number of peer-reviewed journals in the areas of medical virology and anti-viral strategies. He is the current elected President of the Asia-Pacific Society of Medical Virology (2019 to 2024) and the current elected President of the Singapore Society for Microbiology and Biotechnology.